1279. Real World Treatment Experience of Treatment-Naïve People with HIV who Initiated Treatment with Single Tablet Dolutegravir/Lamivudine in a Test and Treat setting in the US.

BACKGROUND: Dolutegravir/lamivudine (DTG/3TC) is indicated as a 2DR for both treatment-naïve and virally suppressed PLWH. The feasibility of DTG/3TC use in a Test & Treat (T&T) setting has been demonstrated in a clinical trial, but there is limited evidence with this approach in US real worl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuretski, Jennifer, Donovan, Cindy, Harper, Gavin, Merrill, Deanna, Mycock, Katie L, Oglesby, Alan, Metzner, Aimee, Patarroyo, Jimena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752799/
http://dx.doi.org/10.1093/ofid/ofac492.1110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752799/
http://dx.doi.org/10.1093/ofid/ofac492.1110

Ejemplares similares